Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

This study is currently recruiting participants.

Verified by Karolinska Institutet, December 2006

First Received: January 10, 2007 No Changes Posted

Sponsors and Collaborators:	Karolinska Institutet Stockholm County Council Aerocrine AB Phadia AB Meda AB Swedish Research Council Swedish Council on Working Life and Social Research MSD Sweden
Information provided by:	Karolinska Institutet
ClinicalTrials.gov Identifier:	NCT00421018

Purpose

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

Condition	Intervention
Allergic Asthma	Device: Use of exhaled NO as a guide to regulate asthma treatment

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)

Resource links provided by NLM:

MedlinePlus related topics: Asthma

U.S. FDA Resources

Further study details as provided by Karolinska Institutet:

Primary Outcome Measures:

Mini-AQLQ (Asthma-Related Quality of Life)

Estimated Enrollment:	200
Study Start Date:	November 2006
Estimated Study Completion Date:	April 2009

Eligibility

Ages Eligible for Study:	18 Years to 64 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18-64
Clinical diagnosis of Asthma
Glucocorticoid treatment > 6 months.
Verified Allergy
Read and speak Swedish

Exclusion Criteria:

Smoking
Current regular treatment with long-acting beta2-agonist
Treatment with Singulair only or in combination with glucocorticoids
Taking part in other research study
Pregnancy or breast-feeding
Unstable Asthma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00421018

Contacts

Contact: Jörgen Syk, M.D.

+46 8 590 990 60

Jorgen.Syk@ptj.se

Locations

Sweden
Karolinska Institutet	Recruiting
Stockholm, Sweden, SE-171 76
Principal Investigator: Kjell Alving, PhD

Sponsors and Collaborators

Karolinska Institutet

Stockholm County Council

Aerocrine AB

Phadia AB

Meda AB

Swedish Research Council

Swedish Council on Working Life and Social Research

MSD Sweden

Investigators

Principal Investigator:

Kjell Alving, Ph.D

Karolinska Institutet

More Information

No publications provided

Study ID Numbers:	20050166
Study First Received:	January 10, 2007
Last Updated:	January 10, 2007
ClinicalTrials.gov Identifier:	NCT00421018 History of Changes
Health Authority:	Sweden: The Ministry of Education and Cultural Affairs

Keywords provided by Karolinska Institutet:

Asthma
Allergy
Cytokines
Glucocorticoids
Inflammation

Nitric Oxide (NO)
Quality of Life
Self-Rated Health
Stress

Study placed in the following topic categories:

Bronchial Diseases
Asthma
Stress
Quality of Life
Glucocorticoids
Inflammation
Nitric Oxide

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Hypersensitivity
Lung Diseases, Obstructive
Immune System Diseases
Respiratory Tract Diseases
Bronchial Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on September 09, 2009